Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Soon Auck | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Hong, Sook Hee | - |
dc.date.accessioned | 2024-01-09T14:36:29Z | - |
dc.date.available | 2024-01-09T14:36:29Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 0008-5472 | - |
dc.identifier.issn | 1538-7445 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70515 | - |
dc.description.abstract | Purpose: EGFR tyrosine kinase inhibitor (EGFR TKI) was approved as a first line treatment for EGFR mutant lung adenocarcinoma (LADC) with advanced stage. YAP1 (Yes-associated protein 1) is a main effector of hippo pathway, related with adverse prognosis and EGFR TKI modulation of non-small cell lung cancer. This study aimed to clarify a prognostic role of YAP1 in EGFR mutant LADC and efficacy for EGFR TKI through the course of EGFR TKI. Materials and Methods: 41 patients with paired lung cancer specimen before and after EGFR TKI were enrolled in this study. The expression of YAP1 protein was evaluated by immunohistochemistry. Results: 15 cases (36.6%) with high YAP1 expression was found in pre-EGFR TKI LADC, while high YAP1 expression in 21 cases (52.5%) was detected after EGFR-TKI. The transitional level of YAP1 between pre- and post-EGFR TKI was significantly upregulated (P=0.002). High YAP1 before EGFR TKI was related with shorter OS (P=0.023) and PFS (P=0.041). In addition, high YAP1 before EGFR TKI in T790M mutant LADC was related with poor OS (P<0.001). Conclusion: YAP1 burden before EGFR TKI was crucial role in prognosis of EGFR mutant LADC treated by EGFR TKI. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.title | Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival | - |
dc.type | Article | - |
dc.identifier.doi | 10.1158/1538-7445.AM2018-2609 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH, v.78, no.13 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000468819500010 | - |
dc.citation.number | 13 | - |
dc.citation.title | CANCER RESEARCH | - |
dc.citation.volume | 78 | - |
dc.type.docType | Meeting Abstract | - |
dc.publisher.location | 미국 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.